Connection

Anand Sharma to Receptor, ErbB-2

Back to Details
This is a "connection" page, showing publications Anand Sharma has written about Receptor, ErbB-2.
Anand Sharma
Connection Strength
0.185
Receptor, ErbB-2
  1. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022 02; 23(2):259-269.
    View in: PubMed
    Score: 0.185
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.